Authors’ Response

We appreciate the insightful letter-to-editor 1 on our study of the efficacy and safety of an adalimumab biosimilar in axial spondyloarthritis (axSpA). 2 We acknowledge the concern regarding the duration of latent tuberculosis infection (LTBI) prophylaxis.The three-month daily isoniazid plus rifampicin (3HR) regimen used in our cohort is a WHO-recommended LTBI treatment and is endorsed by the Indian National TB Elimination Programme, particularly in high TB-burden settings. 3,4Short-course rifamycinbased regimens are prioritized globally to maximize treatment completion and safety, factors that are paramount in managing chronic inflammatory diseases.While international guidelines often cite rifapentinebased regimens (such as 3HP) as a standard, these are currently not widely available in the Indian market, making the 3HR regimen the most evidence-based and pragmatic short-course option in our setting.